about
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Emerging treatments in type 2 diabetes: focus on canagliflozin.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.The importance of synthetic drugs for type 2 diabetes drug discovery.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.A case of "pseudo-ketoacidosis".Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
P2860
Q33759610-2A5E8094-F67D-4966-9EC1-B2BDCA688139Q34109789-25797FAE-3B83-4301-A133-9920D9FF7DADQ34397646-B26CB143-7918-48A2-B383-0253AC590113Q36022710-B0C5E912-2EFE-4A69-8DB9-9A72F84A9D6DQ36843902-190FB8AC-A8B6-4DFE-ACC4-05C431B10F28Q38139508-463B4BC7-7957-4F1E-AB06-B47916582ADDQ38175467-51FB84D2-E44E-4D9B-B113-90F348B75890Q38250445-7EE7F2C5-05BA-406D-87E5-8A0E6F8C482EQ38389823-BDC455F8-DF2B-4132-9977-DFCB8CE67EF2Q38619164-96E0EE7E-AD26-4565-AC2E-27B490209B05Q38669170-84F37305-035E-433C-AA2E-6CEDCB355253Q38845574-664ED856-5C3D-48DB-B5EE-385165624C7BQ38990518-02CD892F-65A8-439F-AA53-262D878FCFF6Q41846233-9FE28369-07CD-4B2D-AC39-AB4DC52D098BQ46207930-6C4BFA02-84A7-4D3C-8E80-7F2356E1EBA0Q51319263-B9E5D7A6-A648-49BD-A14A-C57866616202Q51679305-01AF972E-0EEF-4114-95C2-3E39F007478DQ51737719-A49D2511-AD65-483A-9D05-63D47B2D3DCAQ53109271-347C2325-E999-462B-95E8-6A08D8C7C10B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Canagliflozin: first global approval.
@en
type
label
Canagliflozin: first global approval.
@en
prefLabel
Canagliflozin: first global approval.
@en
P2860
P1433
P1476
Canagliflozin: first global approval.
@en
P2093
Shelley Elkinson
P2860
P2888
P304
P356
10.1007/S40265-013-0064-9
P577
2013-06-01T00:00:00Z
P5875
P6179
1047489277